Epitranscriptomic regulation of HIF-1: bidirectional regulatory pathways

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F25%3A00618501" target="_blank" >RIV/86652036:_____/25:00618501 - isvavai.cz</a>

Alternative codes found

RIV/67985823:_____/25:00618501 RIV/00216208:11310/25:10501989

Result on the web

<a href="https://doi.org/10.1186/s10020-025-01149-x" target="_blank" >https://doi.org/10.1186/s10020-025-01149-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s10020-025-01149-x" target="_blank" >10.1186/s10020-025-01149-x</a>

Result language

angličtina

Original language name

Epitranscriptomic regulation of HIF-1: bidirectional regulatory pathways

Original language description

Background Epitranscriptomics, the study of RNA modifications such as N6-methyladenosine (m(6)A ), provides a novel layer of gene expression regulation with implications for numerous biological processes, including cellular adaptation to hypoxia. Hypoxia-inducible factor-1 (HIF-1), a master regulator of the cellular response to low oxygen, plays a critical role in adaptive and pathological processes, including cancer, ischemic heart disease, and metabolic disorders. Recent discoveries accent the dynamic interplay between m(6)A modifications and HIF-1 signaling, revealing a complex bidirectional regulatory network. While the roles of other RNA modifications in HIF-1 regulation remain largely unexplored, emerging evidence suggests their potential significance. Main body This review examines the reciprocal regulation between HIF-1 and epitranscriptomic machinery, including m(6)A writers, readers, and erasers. HIF-1 modulates the expression of key m(6)A components, while its own mRNA is regulated by m(6)A modifications, positioning HIF-1 as both a regulator and a target in this system. This interaction enhances our understanding of cellular hypoxic responses and opens avenues for clinical applications in treating conditions like cancer and ischemic heart disease. Promising progress has been made in developing selective inhibitors targeting the m(6)A -HIF-1 regulatory axis. However, challenges such as off-target effects and the complexity of RNA modification dynamics remain significant barriers to clinical translation. Conclusion The intricate interplay between m(6)A and HIF-1 highlights the critical role of epitranscriptomics in hypoxia-driven processes. Further research into these regulatory networks could drive therapeutic innovation in cancer, ischemic heart disease, and other hypoxia-related conditions. Overcoming challenges in specificity and off-target effects will be essential for realizing the potential of these emerging therapies.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Molecular Medicine

ISSN

1076-1551

e-ISSN

1528-3658

Volume of the periodical

31

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

105

UT code for WoS article

001447417800003

EID of the result in the Scopus database

2-s2.0-105000244892